This trial will compare the effectiveness of mosunetuzumab+polatuzumab vedotin to rituximab+gemcitabine+oxaliplatin in people with relapsed or refractory DLBCL, high-grade B-cell lymphoma, transformed follicular lymphoma, and FL3B.
- Non-Hodgkin's Lymphoma
1 Primary · 16 Secondary · Reporting Duration: Up to 2 years
Awards & Highlights
2 Treatment Groups
M+P (Arm A)
1 of 2
R-GemOx (Arm B)
1 of 2
222 Total Participants · 2 Treatment Groups
Primary Treatment: M+P (Arm A) · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
- 2022. "A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05171647.
Frequently Asked Questions
Is R-GemOx (Arm B) a new medication?
"As of right now, 1225 different clinical studies are running that involve R-GemOx (Arm B). 342 of those active studies are in Phase 3. The majority of studies for R-GemOx (Arm B) are based in Guangzhou, Guangdong; however, 52797 total locations across the globe are conducting these sorts of trials." - Anonymous Online Contributor
Does R-GemOx (Arm B) have FDA approval?
"R-GemOx (Arm B) has undergone Phase 3 clinical trials, meaning that there is available data supporting both its efficacy and safety. Our team at Power rates the safety of R-GemOx highly, with a score of 3." - Anonymous Online Contributor
What is the total size of the study's test group?
"That is correct. The clinicaltrial.gov website shows that this trial, which was originally posted on April 25th, 2022, is still recruiting patients. They are looking for 222 participants at 1 site." - Anonymous Online Contributor
What is the standard treatment that R-GemOx (Arm B) is used to manage?
"R-GemOx (Arm B) is the standard of care for diffuse large b-cell lymphoma (dlbcl). This treatment option is also effective for small cell lung cancer (sclc), systemic juvenile idiopathic arthritis (sjia), and head and neck carcinoma." - Anonymous Online Contributor
Is it possible to sign up for this research program at the present time?
"The clinical trial, which is currently seeking 222 patients from 1 site, was originally posted on 4/25/2022 and last edited on 11/1/2022 according to information found on clinicaltrials.gov" - Anonymous Online Contributor